PsOPsA Hub’s Post

Can inotuzumab ozogamicin eradicate MRD in adult patients with B-ALL in complete remission? Read our latest article to learn more about the phase II (NCT03441061) trial here 👉 https://loom.ly/9FpJZZk #allsm #leusm #MedEducation

As one of the cofounders of Evinature, I've worked alongside Dr. Prof. Shomron Ben-Horin M.D. to develop the CurQD Protocol, a nutraceutical that’s now helping thousands of IBD patients worldwide. One of the most challenging and often embarrassing symptoms of IBD, particularly ulcerative colitis (UC), is urgency—the sudden, uncontrollable need to find a bathroom. It’s a symptom that can drastically affect quality of life. We’re thrilled to share that CurQD has been proven to help with urgency, too. A post-hoc analysis of a randomized controlled trial (RCT) now published in Journal of Crohn's and Colitis highlights this additional benefit, even though urgency wasn’t the primary outcome of the study. This finding brings us one step closer to addressing the most difficult aspects of living with IBD. We remain committed to supporting the IBD community with safe, effective solutions like CurQD, and this breakthrough further validates our mission. Check out the study here: https://lnkd.in/dTpbJbpW #IBD #CurQD #Urgency #UlcerativeColitis

FUMANBA-1 trial: In patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), a single infusion of equecabtagene autoleucel (eque-cel) resulted in an overall response rate of 96%. https://ja.ma/4fBxnmL

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

According to a prolonged follow-up of the POLARIX trial, treatment with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone showed durable and significant PFS benefit vs R-CHOP among patients with intermediate- or high-risk DLBCL. Learn more:  https://lnkd.in/eyGPFZXp #ASH2024

TOP 10: ASi in CKD by Drs. @KatherineTuttl8, @P_Rossing et al. https://lnkd.in/ek8ZBDN6 The aldosterone synthase inhibitor vicadrostat dose-dependently reduced albuminuria without unexpected safety signals in CKD patients. Join our Webinar on 24th Jan. https://lnkd.in/ejmhh5yg

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa https://lnkd.in/g-ZPvnYs BE HEARD I and BE HEARD II are the first Phase 3 trials to evaluate the efficacy and safety of an IL-17A and IL–17F inhibitor, BIMZELX® (bimekizumab-bkzx), in the treatment of adult patients with moderate-to-severe [...]

🔬 A recent study performed a review and meta-analysis of previously gathered clinical trial data to compare 1st line chemotherapy for advanced pancreatic ductal adenocarcinoma with other treatment options for #PDAC. 👉 Learn more about the efficacy and toxicity of various treatment options: https://buff.ly/40XY1SR #PancreaticCancerAwareness

📢 "ECMO as a Promising Lifeline in Drug Overdose Treatment: Benefits and Risks Unveiled" A recent study published in the Bulletin of Emergency and Trauma, led by Hany A. Zaki and colleagues, provides a thorough examination of the use of extracorporeal membrane oxygenation (ECMO) therapy for treating patients suffering from severe drug overdoses. This systematic review and meta-analysis sheds light on the clinical outcomes, both positive and negative, of ECMO as a critical intervention in cases of drug intoxication. Given the rising prevalence of drug overdoses, especially in emergency settings, understanding the role of ECMO in patient survival is of paramount importance. #ECMO #ECMOTeam #ExtracorporealMembraneOxygenation #CardiopulmonarySupport #ECMOEducation Perfusion Times advocates for content grounded in evidence-based medicine, drawing from prestigious academic journals open access peer-reviewed. #Follow #PerfusionTimes